Access Home Care Solutions, LLC
Access Home Care Solutions, LLC was paid $41K by Medicaid between Oct 2021 and Sep 2024, across 4 billing codes. Its largest line is M0244, Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency — 57% of everything it billed.
SLIDELL, LA 70458
Next to other Home Health Agency providers in Louisiana
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 124 | $17K | |
| 2022 | 64 | $7K | |
| 2023 | 302 | $12K | |
| 2024incomplete | 317 | $5K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| M0244 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency | 57% | 93 | 45 | $24K |
| J7999 | Compounded drug, not otherwise classified | 41% | 593 | 299 | $17K |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 1.5% | 95 | 44 | $634.14 |
| S9328 | Home infusion therapy, implanted pump pain management infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem | 0% | 26 | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.